^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ScTIL210

    i
    Associations
    News

    Trials

    Company:
    Beijing Cancer Hospital, Chineo Medical Technology
    Drug class:
    Immunomodulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (NCT04571892)
    Phase 1/2
    Shanghai East Hospital
    Recruiting
    Last update posted :
    04/12/2023
    Initiation :
    10/15/2020
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    PD-1
    |
    PD-1 positive
    |
    ScTIL210
    Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors (NCT05730361)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    02/15/2023
    Initiation :
    02/01/2023
    Primary completion :
    05/01/2024
    Completion :
    08/01/2024
    PD-1
    |
    PD-1 positive
    |
    ScTIL210